Key result
Medication nonadherence remains a significant barrier to enhancing the effectiveness of existing treatments for patients with chronic heart failure.
Why the study?
Do interventions to enhance adherence to medications improve outcomes in patients with chronic heart failure?
Do interventions to enhance adherence to medications improve outcomes in patients with chronic heart failure?
Answers are grounded in this paper and cite their sources.
Nonadherence to medication remains a significant barrier to enhancing the effectiveness of existing treatments for chronic heart failure.
First paragraph: Prognosis remains poor for patients with chronic heart failure (CHF), despite improvements in the prevention and treatment of heart failure over the last 25 years. Recent estimates indicate that the median survival after a first episode of heart failure is 2.3 years for men and 1.8 years for women. It is suggested that the improvements in outcomes that have been achieved can be partly explained by increases in prescribing rates of medications such as angiotensin-converting enzyme inhibitors, β-blockers, and spironolactone over this period. Although the evidence on medication efficacy for certain subgroups of patients with CHF is clear, there are also compelling data showing that many of these patients do not take their medications as prescribed by health care providers. This "nonadherence" to medication therefore remains a significant barrier to enhancing the effectiveness of existing treatments.
No takes yet. Share an insight, caveat, or question.
Molloy et al. (2012) conducted a review in Chronic heart failure (CHF). Interventions to enhance medication adherence was evaluated. Medication nonadherence remains a significant barrier to enhancing the effectiveness of existing treatments for patients with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: